XM no presta servicios a los residentes de Estados Unidos de América.

N
N

Novartis

Noticias

Reuters - Hace 35 minutos

Novartis: Positive Results For Interim Analysis Of Iptacopan Phase III Study

BRIEF-Novartis: Positive Results For Interim Analysis Of Iptacopan Phase III Study Oct 2 (Reuters) - Novartis Ag NOVN.S : NOVARTIS INVESTIGATIONAL IPTACOPAN PHASE III STUDY DEMONSTRATES CLINICALLY MEANINGFUL AND HIGHLY STATISTICALLY SIGNIFICANT PROTEINURIA REDUCTION IN PATIENTS WITH IGA NEPHROPATHY (IGAN) PHASE III APPLAUSE-IGAN STUDY MET ITS PRE-S
N
Reuters - Hace 3 días

Novartis Completes Divestment Of Ophthalmology Assets To Bausch + Lomb

BRIEF-Novartis Completes Divestment Of Ophthalmology Assets To Bausch + Lomb Sept 29 (Reuters) - Novartis AG NOVN.S : COMPLETES DIVESTMENT OF 'FRONT OF EYE' OPHTHALMOLOGY ASSETS TRANSACTION VALUED UP TO USD 2.5 BILLION, CONSISTING OF 1.75 BILLION IN UPFRONT CASH, PLUS POTENTIAL ADDITIONAL MILESTONE PAYMENTS COMPLETED ITS DIVESTMENT OF 'FRONT OF EYE
N
Reuters - Hace 5 días

Pharma lobby says EU ban on 'forever chemicals' would halt drug production

Pharma lobby says EU ban on 'forever chemicals' would halt drug production By Ludwig Burger FRANKFURT, Sept 27 (Reuters) - European drugmakers warned that a proposed complete ban on substances known as PFAS or " forever chemicals " would render medicine production in the region impossible, part of a high-stakes wrangle between manufacturers and environmental regulators.
B
N
P
Reuters - Hace 6 días

Ionis' metabolic disorder drug lowers high levels of a type of fat in study

UPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in study Adds CEO comment in paragraph 9, background throughout Sept 26 (Reuters) - Ionis Pharmaceuticals IONS.O said on Tuesday its experimental drug met the main goal of reducing abnormally high levels of the most common type of body fat in a late-stage trial in patients with a metabolic disorder.
B
N
Reuters - Hace 6 días

Vontobel sees value from Swiss spin-offs ahead of Sandoz separation

BUZZ-Vontobel sees value from Swiss spin-offs ahead of Sandoz separation ** With spin-off activity high so far this year, Vontobel notes Swiss spin-offs have historically unlocked value for shareholders but is cautious about transactions globally ** "The two most recent and largest spin-offs in Switzerland have been successful, but globally only ha
A
J
N
Reuters - Hace 6 días

Sandoz' MS drug receives approval from European Commission

Sandoz' MS drug receives approval from European Commission ZURICH, Sept 26 (Reuters) - Novartis said on Tuesday its soon to be spun off generic-drugs business Sandoz has received approval from the European Commission for Tyruko (natalizumab), which treats relapsing forms of multiple sclerosis. Tyruko, the first biosimilar for treating multiple sclerosis in Europe, has been approved for all indications of reference medicine, the company said in a statement.
N
Reuters - Hace 1 semana

US stocks may not fall much more over shutdown, could rally after

LIVE MARKETS-US stocks may not fall much more over shutdown, could rally after STOXX Europe 600 down 0.9% China concerns weigh on markets German business sentiment worsens US stock futures inch lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com US STOCKS MAY NOT FALL MUCH MORE OVER SHUTDOWN, COULD RALLY AFTER (1243 GMT ) The Republican-controlled House of Representatives is du
A
B
E
G
N
U
U
B
R
U
E
F
U
Reuters - Hace 1 semana

EU drugmakers: a safe haven with earnings strength

LIVE MARKETS-EU drugmakers: a safe haven with earnings strength STOXX Europe 600 down 0.9% China concerns weigh on markets German business sentiment worsens US stock futures inch lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EU DRUGMAKERS: A SAFE HAVEN WITH EARNINGS STRENGTH (1214 GMT) Morgan Stanley is upbeat about European drug stocks and believes the sector could offer
A
B
E
G
G
N
U
U
B
R
U
E
F
U
G
Reuters - Hace 1 semana

MS sees EU biopharma as 'safe heaven', prefers defensive earnings momentum

BUZZ-MS sees EU biopharma as 'safe heaven', prefers defensive earnings momentum ** Morgan Stanley anticipates EU biopharma to offer a "safe heaven" from weakening growth or higher real yields as it provides relatively high returns in an uncertain macroeconomic backdrop ** As inflationary pressures ease and COVID and inventory adversity fades the EU
A
N
Reuters - Hace 1 semana

Novartis AG: No New Or Unexpected Safety Findings Were Observed In Study And Data Are Consistent With Already Well-Established Safety Profile Of Lutathera

BRIEF-Novartis AG: No New Or Unexpected Safety Findings Were Observed In Study And Data Are Consistent With Already Well-Established Safety Profile Of Lutathera Sept 25 (Reuters) - Novartis AG NOVN.S : NOVARTIS RADIOLIGAND THERAPY LUTATHERA® DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL PROGRESSION-FREE SURVIVAL IN FIRST LINE AD
N
Reuters - Hace 1 semana

Novartis confirms Sandoz spin-off for October 4, 2023

Novartis confirms Sandoz spin-off for October 4, 2023 ZURICH, Sept 25 (Reuters) - Novartis NOVN.S on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month. Novartis also said key regulatory approvals have been obtained, including the approval by SIX Exchange Regulation for the listing of the Sandoz shares on the SIX Swiss Exchange.
N
Reuters - Hace 1 semana

Big Pharma bets on AI to speed up clinical trials

INSIGHT-Big Pharma bets on AI to speed up clinical trials Repeats for additional subscribers By Natalie Grover and Martin Coulter LONDON, Sept 22 (Reuters) - Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.
A
B
N
R
Reuters - Hace 1 semana

Intel antitrust lawyer joins law firm Arnold & Porter in Washington

Intel antitrust lawyer joins law firm Arnold & Porter in Washington By David Thomas Sept 21 (Reuters) - U.S. law firm Arnold & Porter Kaye Scholer said Thursday it has hired the leader of U.S. chipmaker Intel's INTC.O global M&A regulatory practice for its own antitrust practice. David Emanuelson has joined Arnold & Porter's Washington, D.C., office as a partner, the firm said.
I
N
Reuters - Hace 2 semanas

China's BeiGene falls on terminating cancer drug deal with Novartis

BUZZ-China's BeiGene falls on terminating cancer drug deal with Novartis ** Hong Kong shares of Chinese oncology medicines developer BeiGene Ltd 6160.HK fall as much as 6% to HK$119.40, their lowest since Sept 11 ** Stock on course to snap three straight sessions of gain and for biggest one-day pct decline since Aug 7, if losses hold ** Shanghai-li
N
Reuters - Hace 2 semanas

Novartis AG Novartis And Beigene Have Mutually Agreed To Terminate The Collaboration And License Agreement For Tislelizumab

BRIEF-Novartis AG Novartis And Beigene Have Mutually Agreed To Terminate The Collaboration And License Agreement For Tislelizumab Sept 19 (Reuters) - Beigene Ltd 6160.HK : NOVARTIS AG: NOVARTIS AND BEIGENE, LTD. HAVE MUTUALLY AGREED TO TERMINATE THE COLLABORATION AND LICENSE AGREEMENT FOR TISLELIZUMAB NOVARTIS AG: WITH TERMINATION, BEIGENE WILL RE-
N
Reuters - Hace 2 semanas

BeiGene to go solo with cancer drug after Novartis deal termination

UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination Adds Novartis statement in paragraphs 6 and 7, BeiGene comments in paragraph 9, analyst's comment in paragraph 10 By Sriparna Roy Sept 19 (Reuters) - BeiGene 6160.HK and Swiss drugmaker Novartis NOVN.S have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months.
N
Reuters - Hace 2 semanas

BeiGene regains rights for cancer drug after Novartis deal termination

BeiGene regains rights for cancer drug after Novartis deal termination Sept 19 (Reuters) - BeiGene 6160.HK said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis NOVN.S . Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
N
Reuters - Hace 2 semanas

Beigene Announces Termination Of License Agreement With Novartis

BRIEF-Beigene Announces Termination Of License Agreement With Novartis Sept 19 (Reuters) - Beigene Ltd 6160.HK : BEIGENE SWITZERLAND GRANTED NOVARTIS RIGHT TO DEVELOP, MANUFACTURE AND COMMERCIALIZE TISLELIZUMAB BEIGENE SWITZERLAND AND NOVARTIS ENTERED INTO A MUTUAL TERMINATION AND RELEASE AGREEMENT AGREEMENT TO MUTUALLY TERMINATE LICENSE AGREEMENT
N
Reuters - Hace 2 semanas

Sandoz Receives Positive CHMP Opinion For Breast And Gastric Cancer Biosimilar Trastuzumab

BRIEF-Sandoz Receives Positive CHMP Opinion For Breast And Gastric Cancer Biosimilar Trastuzumab Sept 18 (Reuters) - NOVARTIS AG NOVN.S : SANDOZ RECEIVES POSITIVE CHMP OPINION FOR BREAST AND GASTRIC CANCER BIOSIMILAR TRASTUZUMAB POSITIVE CHMP OPINION BASED ON COMPREHENSIVE PACKAGE OF ANALYTICAL, PRE-CLINICAL AND CLINICAL DATA BREAST AND GASTRIC CAN
N
Reuters - Hace 2 semanas

Novartis shareholders vote in favour of Sandoz spin-off

UPDATE 1-Novartis shareholders vote in favour of Sandoz spin-off Adds background on Sandoz CEO interview from 2nd paragraph By Ludwig Burger FRANKFURT, Sept 15 (Reuters) - Novartis NOVN.S shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the complete separation .
N
P

Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Utilizamos cookies para ofrecerle una mejor experiencia en nuestra web. Conozca más o cambie sus ajustes de cookies.

Advertencia de riesgo: Los CFD son un producto difícil de comprender y la CNMV cree que no es adecuado para inversores minoristas dada su complejidad y riesgo. Por favor, lea y asegúrese de que comprende completamente nuestra Declaración de riesgos.